Ongoing clinical trials at NCI that are exclusive to or include patients with ATL:
- Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) (https://clinicaltrials.gov/ct2/show/NCT02689453)
